Essential roles of mitochondrial and heme function in lung cancer bioenergetics and tumorigenesis

Sarada Preeta Kalainayakan†, Keely E. FitzGerald†, Purna Chaitanya Konduri, Chantal Vidal and Li Zhang*

Abstract
Contrary to Warburg’s hypothesis, mitochondrial oxidative phosphorylation (OXPHOS) contributes significantly to fueling cancer cells. Several recent studies have demonstrated that radiotherapy-resistant and chemotherapy-resistant cancer cells depend on OXPHOS for survival and progression. Several cancers exhibit an increased risk in association with heme intake. Mitochondria are widely known to carry out oxidative phosphorylation. In addition, mitochondria are also involved in heme synthesis. Heme serves as a prosthetic group for several proteins that constitute the complexes of mitochondrial electron transport chain. Therefore, heme plays a pivotal role in OXPHOS and oxygen consumption. Further, lung cancer cells exhibit heme accumulation and require heme for proliferation and invasion in vitro. Abnormalities in mitochondrial biogenesis and mutations are implicated in cancer. This review delves into mitochondrial OXPHOS and lesser explored area of heme metabolism in lung cancer.

Background
At the cellular level, energetic transactions underlie all processes. There are several energetic currencies of the cell, but most of these interactions utilize adenosine triphosphate, or ATP. There are two primary pathways to synthesize this important molecule: glycolysis and oxidative phosphorylation. The term glycolysis is derived from the words “glyco,” meaning sweet, and “lysis,” meaning breaking. Therefore, it is unsurprising that glycolysis is the process of breaking down sugar to form cellular energy. The substrate for this process is usually glucose, and two ATP molecules are produced for every molecule of glucose. As this process does not require oxygen, it is alternatively referred to as anaerobic respiration. To begin glycolysis, glucose transporters facilitate glucose uptake [1]. Next, glucose is phosphorylated by hexokinase to become glucose-6-phosphate. Glucose-6-phosphate is then acted on by glucose-6-phosphate isomerase and becomes fructose-6-phosphate. These phosphorylated sugars can then enter the pentose phosphate pathway, creating nucleotides and NADPH, or the glycolytic pathway, which synthesizes lactate. Phosphofructose-1 then facilitates the transformation of fructose-6-phosphate to fructose-1,6 bisphosphate. Fructose-1,6 bisphosphate can either continue down the glycolytic pathway and become glyceraldehyde-3-phosphate or dihydroxyacetone phosphate for use with lipid synthesis (Fig. 1). Glyceraldehyde-3-phosphate is transformed into glyceraldehyde-2-phosphate by glyceraldehyde-3-phosphate dehydrogenase. Enolase then changes glyceraldehyde-2-phosphate into phosphoenolpyruvate (PEP) (Fig. 1). Pyruvate kinase then produces two molecules of ATP and two molecules of pyruvate from two molecules of PEP. Pyruvate is then converted into lactate by lactate dehydrogenase-A, converting NADH to NAD+. NAD+ is critical because it feeds the cyclic nature of the glycolysis (Fig. 1).

Oxidative phosphorylation (OXPHOS), also known as aerobic mitochondrial respiration, is much more complex than glycolysis. As the name suggests, oxidative phosphorylation requires oxygen. It is also slower than glycolysis. However, oxidative phosphorylation is substantially more fruitful than glycolysis. Oxidative phosphorylation is made possible by the mitochondrial respiratory
chain complexes I–V. Oxidative phosphorylation begins when pyruvate is imported into mitochondria through the outer mitochondrial membrane, the intermembrane space, and the inner mitochondrial membrane by mitochondrial pyruvate carrier (MPC). Pyruvate can also be transformed into lactate and nicotinamide adenine dinucleotide (NAD) via lactate dehydrogenase (LDH). Within the mitochondrial matrix, pyruvate is changed to acetyl coenzyme A (acetyl CoA) through pyruvate dehydrogenase catalysis. Acetyl CoA combines with oxaloacetate in the first step of the tricarboxylic acid cycle (TCA cycle, Fig. 1), and through organic acid oxidation, succinate is formed. NADH then donates electrons to the electron transport chain, which includes mitochondrial complexes I–IV (Fig. 2). Mitochondrial complex I, also known as NADH dehydrogenase or NADH ubiquinone oxidoreductase, is the largest mitochondrial complex and begins the electron transport chain [2]. Electrons then shift from mitochondrial complex I to cytochrome Q. Some electrons come directly to cytochrome Q from NADH. Flavin-containing enzyme complexes mediate this transition of electrons [3] (Fig. 2). Complex II or III can both be the next destination for these electrons. Succinate becomes reduced, and these electrons come to cytochrome Q or complex III. Complex III and cytochrome c then pass on electrons to complex IV. A proton gradient is formed by complexes I, II, IV as they pass electrons over the inner mitochondrial membrane. Protons then enter the mitochondrial matrix with the help of complex V, ATP synthase, and result in the production of ATP. Complexes I–V allow oxidative phosphorylation and can produce up to 38 mol ATP per mol of glucose (Figs. 1 and 2). The importance of TCA cycle and oxidative metabolism in lung cancer is highlighted by recent studies of NSCLC tumors in human patients showing that glucose metabolites from enhanced glycolysis and lactate enter and intensify the TCA cycle, although NSCLC tumors are metabolically heterogeneous [4, 5]. A study using genetically engineered mouse models (GEMMs) for lung cancer (Kras<sup>LSL-G12D</sup>/+Trp53<sup>−/−</sup> and Kras<sup>LSL-G12D/Lkb1<sup>−/−</sup></sup>) showed that the contribution of lactate to the TCA cycle is higher than that of glucose [6]. Additionally, components of OXPHOS complexes and markers of mitochondrial biogenesis are found to be highly predictive of reduced overall survival in NSCLC patients [7]. Likewise, the expression of OXPHOS genes is negatively correlated with the prognosis of lung adenocarcinoma [8].

**Prominent genetic differences exist between healthy tissue and lung cancer tissue**

The value of genetic drivers in lung cancer cannot be overstated. It is believed that up to 60% of lung adenocarcinomas have driver mutations. These mutations most commonly occur in proto-oncogene B-Raf (BRAF), Kirsten rat sarcoma viral oncogene (KRAS), anaplastic lymphoma kinase (ALK), and epidermal growth factor receptor (EGFR) [9]. In lung cancer, the EGFR pathway is the main signaling pathway. The mutation rate of genes in the EGFR pathway are as high as 70–80% in lung cancer tissues [9, 10]. This high rate is attributable to the fact that EGFR can act via the PI3K/AKT/mTOR, RAS/RAF/MAPK and JAK/STAT signalling pathways [11–13]. Activating mutations in EGFR lead to constitutive tyrosine kinase activation and oncogenic transformation of lung epithelial cells in vitro [13, 14]. Activating mutations of EGFR were found in 10–15% of unselected Western patients [15–18] and 30–40% of Asian patients [19–21].

KRAS mutations are responsible for around 30–35% of lung adenocarcinoma genetic variation, 97% of which occur on codon 12 or 13 [9]. Ras mutations frequently occur in human cancers [22]. Insensitivity to GTPase-activating proteins is caused by activating mutations in Ras guanosine nucleotide-binding proteins [23]. Glucose uptake and flux, important for the survival and proliferation of lung cancer, are partially promoted by activated GTP-bound Ras family members. Oxygen consumption and tricarboxylic acid cycle activity are also increased by activated Ras, further fueling the metastatic capacity of cancer cells. Ras activates cytochrome c oxidase, a vital component of complex IV of the electron transport chain containing 10 genomic DNA-encoded subunits and 3 mitochondrial DNA-encoded subunits [24, 25]. The levels of cytochrome c oxidase are elevated in some forms
of cancer [25, 26]. A549, a lung adenocarcinoma cell line, is unable to grow without activated cytochrome c oxidase [23]. Ras mutations are far from the only nuclear genes with frequent mutations in lung cancer. Genes for isocitrate dehydrogenase, including IDH1 and IDH2, and succinate dehydrogenase, including SDHB, SDHC, and SDHD, code for mitochondrial components [27]. As structure determines function, the deformities caused by these mutations affect mitochondrial function. This altered mitochondrial function is either causal to or associated with lung cancer.

In addition to genomic differences, lung adenocarcinoma exhibits proteomic differences. ATP synthase subunit d (ATP5D) are expressed in much higher levels in cancerous tissues than in healthy tissues [28]. Similarly, two important enzymes associated with aerobic glycolysis and fatty acid synthesis, malic enzyme (ME) and ATP citrate lyase (ACLY), are highly associated with non-small cell lung cancer (NSCLC) cells. ME catalyzes decarboxylation of malate to yield pyruvate and CO2, accompanied by the production of NADH or NADPH. ACLY is a key enzyme of de novo fatty acid synthesis responsible for generating cytosolic acetyl-CoA and oxaloacetate from citrate. Akt directly phosphorylates and activates ACLY [29]. The expression levels of phospho-Akt and phospho-ACLY are positively correlated, and ACLY is directly activated by the PI3K-Akt pathway in lung adenocarcinoma cell lines [30]. Activated ACLY is a negative prognostic factor in human lung adenocarcinomas. ME correlates with metastases to mediastinal lymph nodes and ATP-citrate lyase correlates with local tumor stage. Interestingly, upregulation of these two enzymes is associated with increased survival rates in young patients and decreased survival rates in elderly patients [31]. ME levels are also increased in the lung tissues of smokers compared to non-smokers [31]. Nonsmokers, however, are believed to have adenocarcinomas that evolve locally. Non-smokers with adenocarcinoma displayed four times as many differentially expressed genes than smokers with adenocarcinoma did [32]. Lung adenocarcinomas are the most common form of NSCLCs found in non-smokers. Interestingly, non-smokers and smokers appear to follow very different modes of tumorigenesis. It is believed that in smokers with adenocarcinoma, a small area within the lung becomes genetically altered. From there, it evolves into cancer. Fascinatingly, the level of upregulation of some genes in smokers is correlated with the frequency that the smoker smoked [32].
From the enormous body of research on the genetic basis of lung cancer, it is obvious that lung cancer is highly genetically heterogeneous. Therefore, it is unsurprising that chemo-resistance is a major problem for lung cancer patients. Any resistant cells will replicate after the cancer is subjected to the first treatment, and therefore the drug will quickly lose efficacy in a heterogeneous tumor as the tumor acquires genetic and epigenetic changes [33]. Understanding both inter-tumoral and intra-tumoral heterogeneity is consequently of great value when seeking combination therapies for lung cancer.

**Elevated heme uptake and synthesis are hallmarks of NSCLC cells**

Iron protoporphyrin IX, also known as heme, is linked with oxygen utilization, transport, and storage. Heme enters cells through two pathways. Most mammalian cells possess machineries allowing de novo synthesis of heme. In addition, most cells possess heme transporters, such as HCP1 (heme carrier protein 1) and HRG1 (heme related gene 1), for heme uptake. Heme serves as a prosthetic group for hemoglobin, myoglobin, catalases, peroxidases, cytochromes, and several mitochondrial respiratory complexes (Fig. 2) [34, 35]. Heme also has a plethora of biological functions, and is important for circadian rhythm, pancreatic development, neurogenesis, and erythroid biogenesis [36]. Heme directly regulates many vital cellular processes that include cell cycle, cell death, transcription, and translation [37–41]. Abnormal levels of heme are associated with diverse disease states, including anemia; porphyria; neurodegenerative disorders; type-II diabetes; coronary heart disease; and lung, pancreatic, and colorectal cancers [37, 42]. Therefore, heme levels are tightly regulated.

There have been a plethora of epidemiological studies linking dietary heme or red-meat intake with increased risks of several cancers [37, 43–46]. A meta-analysis by Gnagnarella et al. [47] showed that high consumption of red meat is associated with significantly higher risk of lung cancer. A previous review article extensively discussed epidemiological studies linking dietary heme intake with increased risks of various cancers [37]. Thus, this article will focus mainly on the molecular and cellular actions of heme germane to lung cancer. Studies from the authors’ lab implicated heme in lung cancer development [37, 42]. We have shown that NSCLC cell lines exhibited elevated levels of heme synthesis relative to the nontumorigenic cell line HBEC30KT representing normal cells. Inhibition of the rate-limiting heme synthetic enzyme 5-aminolevulic acid synthase (ALAS1) resulted in inhibition of cell proliferation and migration of NSCLC cell lines [42]. This suggests that heme is crucial for progression and metastasis of NSCLC cell lines, albeit in vitro. NSCLC cells also exhibited elevated OXPHOS and elevated expression of oxygen-utilizing hemoproteins, such as CYP1B1 (cytochrome P450 family 1 subfamily B member 1) and cytoglobin. One important function of heme is to serve as a cofactor or prosthetic group for many proteins and enzymes, particularly those involved in oxygen transport, oxygen utilization, and oxygen detoxification [36]. Elevated heme synthesis and uptake should increase cellular heme availability and intensify the synthesis of oxygen-utilizing hemoproteins to support tumorogenic functions [37]. Hemoproteins constitute the mitochondrial electron transport chain complexes that carry out mitochondrial OXPHOS for energy production [42]. Notably, one enzyme in glycolysis, GAPDH (glyceraldehyde-3-phosphate dehydrogenase), has been shown to have a function in heme delivery [48] (Fig. 1) while multiple subunits require heme (Fig. 2). These provide intrinsic links between heme and OXPHOS and cellular bioenergetics.

**Mitochondrial DNA mutations and changes in copy number are associated with lung cancer**

Somatic and germline mitochondrial mutations may both be carcinogenic. However, while most DNA within the body is protected by histones and introns, mitochondrial DNA lacks these important safeguards [49]. Mitochondria also lack DNA-repair machineries present in the nucleus [50]. Therefore, mitochondrial DNA is especially prone to mutations when exposed to reactive oxygen species (ROS). The resulting instability causes both changes in copy number and mutations [51].

According to the multiple hit hypothesis, mitochondrial DNA may function as a complementary gene mutation or as a driver, allowing cancer cells to possess increased clonogenic and/or mutagenic capabilities [51]. Mitochondria increase their copy number substantially to avoid these mutations. The copy number may be changing during the epithelial-to-mesenchymal transition, which is thought to be the most important stage for metastatic potential [52]. For example, in A549 cells, copy number increased from 1700 to 2800 during the epithelial-to-mesenchymal transition. According to some studies, carcinogenicity is correlated with the copy number of mitochondrial DNA, an association drawn especially in lung adenocarcinoma [53–55]. The sets of genes associated with the tricarboxylic acid cycle and the respiratory electron transport have the strongest correlation. However, this may be skewed by diseases that cause both cancer and increased mitochondrial copy number. To ascertain whether this relationship holds true outside of latent diseased states, peripheral white blood
cells were tested for increased mitochondrial DNA copy number. These studies indicated that even after correcting for latent disease, mitochondrial copy number is still associated with increased risk of lung cancer [49]. Lung adenocarcinoma is noted to exhibit increased copy number. However, this is not true for all forms of cancer, as is evidenced by some cancers that are associated with decreased copy numbers [54, 55].

Another factor affecting mitochondrial copy number is the expression of transcription factor A, mitochondria, also known as TFAM [55]. Because TFAM binds to mitochondrial DNA, it helps control mitochondrial gene expression. TFAM expression is positively correlated with mitochondrial DNA copy number [55, 56].

Genes associated with mitochondrial respiration are also differentially expressed in lung tumor cells. In lung adenocarcinoma, 1000 differentially expressed genes, including 535 upregulated genes and 465 down regulated genes, were found utilizing matched tissues from the same patient. Genes associated with the mitochondrial oxidative phosphorylation and the electron transport chain constitutes one class of differentially upregulated genes. UQCRNC2, UQCR11, NDUF1, NDUF2, NDUF4, NDUF5, NDUF6, NDUF7, and ATP5D are related to bioenergetic pathways, including the electron transport chain and mitochondrial ATP synthesis coupled to electron transport [9]. Genes specific to mitochondrial biogenesis are also upregulated in circulating lung cancer cells and seem to be imperative for metastatic potential. For example, peroxisome proliferator-activated receptor gamma coactivator 1 alpha, also known as PGC-1α, was found to increase oxygen consumption, mitochondrial biogenesis, and oxidative phosphorylation, thereby fueling metastases. Interestingly, LeBleu et al. [57] found that PGC-1α only seemed to affect metastases, and had no demonstrated effect on cancer cell proliferation, epithelial-to-mesenchymal transfer, or primary tumor growth.

**Inhibition of mitochondrial function inhibits lung tumor progression**

Oxidative phosphorylation is crucial for anchorage-independent cancer cell proliferation [58]. Suppression of oxidative phosphorylation substantially limits the tumorigenic capacity of cancer cells. Targeting mitochondria, which are necessary for the electron transport chain and oxidative phosphorylation, starves cancer cells of ATP and limits growth and metastasis of tumors. Studies have shown intensified oxygen consumption in NSCLC cell lines HCC4017 when compared to the normal HBEC30KT cells isolated from the same patient. Hypoglycemia also correlates with higher oxygen consumption and encourage glutamine consumption in lung cancer cells. Conversely, low levels of glutamine correlate with low oxygen consumption and encourage glucose utilization [59]. Therefore, when mitochondria are targeted, lung tumor cells become more susceptible to cytotoxic drugs. Several treatments have been shown to interfere with normal mitochondrial function in lung tumor cells, including metformin, BAY87-2243, a lead structure; and microRNA-126 [60–63]. These treatments target different aspects of mitochondrial function.

Cyclopamine, a known inhibitor of Hedgehog signaling pathway, has been shown to exhibit anti-carcinogenic properties. Cyclopamine tartrate, a water-soluble analog of cyclopamine, and is therefore, a better potential therapeutic agent. Cyclopamine and cyclopamine tartrate inhibit smoothened (SMO), which facilitates Hedgehog signaling. This agent also generates ROS, which perturb tumor cell mitochondria. Cyclopamine tartrate can induce mitochondrial fission and fragmentation in some NSCLC cell lines, including A549, H1299, and H460 cells, impeding mitochondrial respiration [60].

Metformin, which has been historically used to alleviate type II diabetes, was noted in 2001 to have anticancer properties in mammals [64]. Patients taking metformin also had fewer instances of cancer than individuals who did not [65–69]. Metformin reduces oxygen consumption in the presence of pyruvate and malate, starving mitochondrial complex I of its substrate: NADH. Metformin may also disrupt the lipid metabolism, glucose metabolism, tricarboxylic acid cycle, the methionine cycle, the folate cycle, and nucleotide synthesis [64, 70–72].

Although most cells have mitochondria, not all cells are strongly affected by mitochondrial inhibitors. Healthy cells likely have lower energy requirements than tumor cells and consequently are not as strongly affected my mitochondrial inhibitors. Healthy cells can maintain functionality even in the presence of mitochondrial inhibitors, making these agents viable treatment options.

**Stromal cells in the tumor microenvironment contribute bioenergetics molecules to cancer cells**

Although mitochondria face substantial challenges in tumor cells and normal metabolic processes are deregulated, tumors retain an astounding capacity to perform oxidative phosphorylation. This is partially due to surrounding tissues fueling the tumor tissue [73]. This process was proposed through a two-compartment model in 2012 [74–76]. It is believed that glycolytic stromal cells produce both ketone bodies and l-lactate, which are used by oxidative epithelial cancer cells [77] (Fig. 3). These fibroblasts and adipocytes produce metabolites, which are then consumed by cancer cells to fuel cancer cell proliferation (see Fig. 3). Glycolytic cancer cells release
lactate, which diffuses along its concentration gradient from the tumor towards blood vessels. Blood vessels eventually clear lactate [78]. In clinical tumors, the lactate amounts to 10–40 mM [79]. In addition to lactate, tumor cells also produce and secrete ammonia [80]. Lactate and ammonia secreted by some cancer cells can be taken up by cancer cells for synthesizing membranes. Skeletal muscles undergo proteolysis and secrete amino acids in response to pro-inflammatory cytokines released by cancer cells.

**Mitochondria and OXPHOS play a pivotal role in drug resistance**

Drug resistance is one of the major hurdles of an effective cancer therapy [92]. Numerous studies have shown that tumors that regress considerably in response to targeted therapy relapse as a more aggressive drug resistant form. Some populations of the cells remain dormant during therapy and subsequently become resistant. The resistant cells continue to establish their clonal populations, metastasis, and result in poor survival outcomes [92]. Therefore, tackling drug resistance is very vital to improve the treatment outcome.

Mitochondria have long been associated with ATP generation and ROS production in cancer. In this section we are delving into much lesser known roles of mitochondria in cancer cell survival and drug resistance. Recent studies have shown that several cancers have adapted and rewired their cells to rely more on mitochondrial OXPHOS for drug resistance [93–98]. Cancer cells have shifted gears to elevated OXPHOS through several different mechanisms ranging from gene upregulations to ectopic protein expressions [93, 99].

Cancer stem-like cells (CSCs) are associated with metastasis and resistance to adjuvant chemotherapy and radiotherapy [93]. Triple negative breast cancer (TNBC) exhibiting markers of CSCs are associated with poor outcomes. A recent study has shown that proto-oncogene MYC (a human gene over-expressed in various cancers that is homologous to an oncogene carried by the avian myelocytomatosis virus) and MCL1 (myeloid cell leukemia-1) protein (stimulates mitochondrial respiration when localized in mitochondrial matrix) are enhanced in CSCs of TNBC [93]. Both MYC and MCL1 promote OXPHOS. Elevated OXPHOS induced ROS which in turn activated HIF-1α, thereby conferring resistance to adjuvant chemotherapy [93, 95]. Similar observation...
was made in small cell lung cancer (SCLC) where CSCs exhibit elevated OXPHOS and preferential dependence on OXPHOS over glycolysis for energy. Oligomycin, an inhibitor of OXPHOS, abolished the tumor initiating abilities of CSCs, thereby implicating the role of OXPHOS in initiation of SCLC [100]. Similarly, NSCLC cells that are resistant to EGFR tyrosine kinase inhibitors, gefitinib and erlotinib, were shown to exhibit elevated OXPHOS accompanied by elevated glycolysis and activity in TCA cycle [99]. This metabolic shift to increased OXPHOS was found to be a result of MET (mesenchymal–epithelial transition factor) proto-oncogene expression in the mitochondrial membrane in addition to plasma membrane. Pharmacological inhibition of MET resulted in cytotoxicity and apoptosis [99]. Interestingly, cancer cells rewire metabolism by altering the localization of proteins and expressing them ectopically in mitochondria [93, 99]. 3-Oxoacid CoA-transferase 1 (OXAT1) and acetyl-CoA acetyltransferase 1 (ACAT1) are proteins localized in mitochondria and are involved in utilization of ketone bodies to aid in tumor growth and metastasis. Epithelial cancers like breast cancer overexpress these mitochondrial proteins to utilize ketone bodies like 3-hydroxybutyrate and acetoacetate for fuel to promote tumor progression and metastasis in lungs [93, 99]. It has been shown by in silico drug designing and mammoomics assay that targeting the mitochondrial proteins—OXAT1 and ACAT1—can effectively inhibit activity and propagation of CSCs in breast cancer [101].

Activating mutations in KRAS oncogene is prevalent in lung, colon, and pancreatic cancers. A recent study that performed a CRISPR/Cas9 screening, identified several mitochondrial genes involved in ribosomes and translation shared lethal interactions with K-ras gene [102]. In renal cell carcinoma (RCC), an NADPH oxidase isoform, NOX4, localizes to the inner mitochondrial membrane, and subcellular redistribution of ATP levels from the mitochondria activates NOX4. NOX4-derived ROS inhibits P300/CBP-associated factor (PCAF)-dependent acetylation and lysosomal degradation of the pyruvate kinase-M2 isoform (PKM2). Silencing NOX4 sensitizes cultured and ex vivo freshly isolated RCC cells to etoposide-induced cell death in xenograft models and ex vivo cultures by acting via PKM2 [103].

A recent study showed that cisplatin-resistant lung adenocarcinoma cells exhibit higher mitochondrial membrane potential (MMP) and intracellular ATP levels than the non-resistant cells which confer migratory and invasive abilities to these cells [8]. Inhibition of mitochondrial complex I abolished the ability of the resistant cells to invade [8], suggesting the pivotal role of mitochondria in metastasis of resistant cells. Another recent study showed that mitochondrial oxygen consumption is a vital source of energy in paclitaxel-resistant lung adenocarcinoma cells [94]. In lung adenocarcinoma cell line A549, mitochondrial membrane depolarization increased during the initial phase where cells died in response to paclitaxel. However, as the cells gained resistance, normal mitochondrial membrane are restored by increased activity of catalase and glutathione peroxidase which counteracted the effect of increased ROS produced as result of paclitaxel treatment. Further, paclitaxel-resistant cells exhibited elevated extracellular acidification rates and oxygen consumption [94]. Several studies have shown that many cancer cells which are resistant, rely on mitochondrial oxidative phosphorylation for energy [96–98]. For example, cytarabine-resistant cells from PDX models of leukemia exhibited higher mitochondrial mass and consequently higher OXPHOS and ATP production [104].

Besides elevation of oxidative phosphorylation and oxygen consumption, several recent studies have shown that genes involved in mitochondrial biogenesis, mitochondrial electron transport chain, mitochondrial transcription factors as well as mitochondrial fission and fusion mediators are upregulated in resistant cancer cells [96–98, 105]. There is evidence that signaling axis involving TFAM—a transcriptional factor involved in mitochondrial biogenesis—is involved in conferring resistance to MAP Kinase inhibitors in melanoma. Additionally, cancer stem cells that are implicated in tumor progression and drug-resistance also exhibit elevated OXPHOS and depend on OXPHOS for energy. These studies showed that regardless of the type of cancer or method of interception, mitochondria play indispensable and multi-faceted roles in resistant cancer cells. Hence, targeting mitochondria could be an effective strategy to suppress drug-resistant cancer cells. Recent studies showed that targeted drug therapies, such as MAPK inhibitors, and first-line chemotherapeutic agents, such as platinum-based drugs, increase mitochondrial activity and OXPHOS [94, 105]. These studies showed that a combination of first-line therapeutic agents and mitochondrial targeting agents would plausibly serve as an effective strategy to curtail tumor progression.

Further, in silico analyses have shown that mitochondrial biogenesis could be used as a reliable factor for predicting outcomes in lung cancer patients [7]. In one study, about 33 mitochondrial-related genes were shown to correlate with NSCLC patient survival [77]. Another recent study showed difference in mitochondrial phenotypes between tumors that depend on glycolysis versus tumors that depend on OXPHOS [106]. Studies are underway to utilize mitochondrial imaging techniques to assess possible modes of prognosis and outcome for a patient [106]. Mitochondria can be specifically targeted
via mitochondrial sirtuins that play an important role in cellular homeostasis and is a major regulator of metabolism in cancer cells. Therefore, it is a potential drug target and further studies are required to assess the ability of targeting mitochondrial sirtuins to specifically target cancer cells [107]. Apart from drugs that particularly target mitochondria, there are several vehicles like PEG coated CNTABT737 nanoparticles that are internalized into early endosomes via micropinocytosis and clathrin-mediated endocytosis and subsequently delivered into mitochondria [108].

Importantly, a recent study from the authors’ lab [109] indicated a link between heme and drug resistance in NSCLC tumor cells. Treatment of subcutaneous xenografts of NSCLC cells with a vascular disrupting agent, combretastatin A4-phosphate (currently in phase II clinical trials for non-squamous NSCLC), results in initial tumor regression followed by relapse. The treatment results in central necrosis; however, cells that constituted the rim of the tumor can proliferate to repopulate the tumor. These resistant cells exhibit increased levels of protein and enzymes involved in heme synthesis and heme uptake, as well as elevated levels of oxygen-utilizing hemoproteins and mitochondrial respiratory chain complex subunits [109].

Conclusions
Clearly, many lines of experimental evidence have convincingly demonstrated the importance of mitochondrial oxidative phosphorylation. As a key signaling and structural molecule for processes involved in oxygen utilization and oxidative metabolism, heme can impact lung tumorigenesis in a multi-faceted manner. It is worth noting that the $K_m$ of heme synthetic enzymes and cytochrome c oxidase for oxygen is very low (< 1 µM or ~ 0.1%) [110–115]. This is below oxygen levels experienced by human cancer cells under hypoxia (0.3–4.2% oxygen saturation) [116]. Thus, both heme synthesis and mitochondrial respiration can be maintained under clinically defined tumor hypoxia. Therefore, the reliance of aggressive or drug-resistant tumor cells on OXPHOS does not conflict with the fact that aggressive and drug-resistant tumors are hypoxic.

Abbreviations
ACAT1: acetyl-CoA acetyltransferase 1; ACLY: ATP citrate lyase; ALAS1: 5-aminolevulic acid synthase; ALK: anaplastic lymphoma kinase; ATP: adenosine triphosphate; CoA: coenzyme A; CRT: chemoradiotherapy; CSCs: cancer stem-like cells; CYP1B1: cytochrome P450 family 1 subfamily B member 1; EGFR: epidermal growth factor receptor; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; Glu: glutamate; GTP: guanosine triphosphate; HCP1: heme carrier protein 1; HRG1: heme related gene 1; KRAS: Kirsten rat sarcoma viral oncogene; LDH: lactate dehydrogenase; MCL1: myeloid cell leukemia-1; ME: malic enzyme; MET: mesenchymal–epithelial transition factor; MPC: mitochondrial pyruvate carrier; NAD: nicotinamide adenine dinucleotide; NADPH: nicotinamide adenine dinucleotide phosphate (reduced form); NSCLC: non-small cell lung cancer; DXAT1: 3-oxoacid CoA transferase 1; OXPHOS: oxidative phosphorylation; PCAF: P300/CBP-associated factor; PEP: phosphoenol pyruvate; PGC-1α: peroxisome proliferator-activated receptor gamma coactivator 1 alpha; PKM2: pyruvate kinase-M2 isofrom; RCC: renal cell carcinoma; ROS: reactive oxygen species; SCLC: small cell lung cancer; TCA: tricarboxylic acid cycle; TFAM: transcription factor A, mitochondria; TNBC: triple negative breast cancer.

Authors’ contributions
KEF, SPK, CK, CV, and LZ contributed to the writing and preparation of the manuscript. KEF and LZ edited the manuscript. LZ conceived the design of the manuscript and figures. All authors read and approved the final manuscript.

Acknowledgements
The preparation of this review is in part supported by Cancer Prevention and Research Institute of Texas Grant RP160617.

Competing interests
The authors declare that they have no competing interests.

Availability of data and materials
Not applicable.

Consent for publication
All authors agree to the publication of this manuscript.

Ethics approval and consent to participate
Not applicable.

Funding
The preparation of this review is in part supported by Cancer Prevention and Research Institute of Texas grant RP160617.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 15 September 2018 Accepted: 26 October 2018
Published online: 02 November 2018

References
1. Zhang Y, Yang JM. Altered energy metabolism in cancer: a unique opportunity for therapeutic intervention. Cancer Biol Ther. 2013;14(2):81–9.
2. Voets AM, Huigsloot M, Lindsey PJ, Leenders AM, Koopman WJ, Willems PH, et al. Transcriptional changes in OXPHOS complex I deficiency are related to anti-oxidant pathways and could explain the disturbed calcium homeostasis. Biochim Biophys Acta. 2012;1822(7):1161–8.
3. Smeenk J, van den Heuvel L, DiMauro S. The genetics and pathology of oxidative phosphorylation. Nat Rev Genet. 2001;2(5):342–52.
4. Hensley CT, Faubert B, Yuan Q, Lev-Cohain N, Jin E, Kim J, et al. Metabolic heterogeneity in human lung tumors. Cell. 2016;164(4):681–94.
5. Faubert B, Li KY, Cai L, Hensley CT, Kim J, Zacharias LG, et al. Lactate metabolism in human lung tumors. Cell. 2017;171(2):358.e9–371.e9.
6. Hui S, Ghergurovich JM, Morcher RJ, Jang C, Teng X, Lu W, et al. Glucose feeds the TCA cycle via circulating lactate. Nature. 2017;551(7678):115–8.
7. Sotgia F, Lisanti MP. Mitochondrial markers predict survival and progression in non-small cell lung cancer (NSCLC) patients: use as companion diagnostics. Oncotarget. 2017;8(40):68095–107.
8. Jeon JH, Kim DK, Shin Y, Kim HY, Song B, Lee DY, et al. Migration and invasion of drug-resistant lung adenocarcinoma cells are dependent on mitochondrial activity. Exp Mol Med. 2016;48(12):e277.
9. Xu H, Ma J, Liu J, Chen L, Sun F, Qu C, et al. Gene expression profiling analysis of lung adenocarcinoma. Braz J Med Biol Res. 2016. https://doi.org/10.1590/1414-431x20154861.

10. Mollberg N, Suriati M, Demchuk C, Fathi R, Salama AK, Husain AN, et al. Mind-mapping for lung cancer: a personalized therapeutics approach. Adv Ther. 2011;28(3):173–94.

11. Scaglotti GV, Selvaggi G, Novello S, Hirsch FR. The biology of epidermal growth factor receptor in lung cancer. Clin Cancer Res. 2004;10(12 Pt 2):4275–32s.

12. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2(2):127–37.

13. Sordella R, Bell DW, Haber DA, Settleman J. Genetic basis of sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in lung cancer. PNAS. 2004;101(24):9306–11.

14. Greulich H, Chen TH, Feng W, Janne PA, Alvarez JV, Zappaterra M, et al. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med. 2005;2(11):e311.

15. Yip PY, Yu B, Cooper WA, Selinger CI, Ng CC, Kennedy CW, et al. Patterns of DNA mutations and ALK rearrangement in resected node negative lung adenocarcinoma. J Thorac Oncol. 2013;8(4):408–14.

16. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005;97(5):639–46.

17. Eberhard DA, Giaccone G, Johnson BE. Biomarkers of response to epidermal growth factor receptor inhibitors in non-small-cell lung cancer working group: standardization for use in the clinical trial setting. J Clin Oncol. 2008;26(9):983–94.

18. Russell PA, Barnett SA, Walkiewicz M, Wainer Z, Conron M, Wright GM, et al. Correlation of mutation status and survival with predominant histologic subtype according to the new IASLC/ATS/ERS lung adenocarcinoma classification in stage I/II (N2) patients. J Thorac Oncol. 2013;8(4):461–8.

19. Kosaka T, Yatabe Y, Endoh H, Kuvano H, Takahashi T, Mitsuosumi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res. 2004;64(24):8919–23.

20. Tokumo M, Toyooka S, Kiura K, Shigematsu H, Tomi K, Aoe M, et al. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small-cell lung cancers. Clin Cancer Res. 2005;11(3):1167–73.

21. Yoshida K, Yatabe Y, Park JY, Shimizu J, Horio Y, Matsuo K, et al. Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutations in patients with non-small cell lung cancer. J Thorac Oncol. 2007;2(1):22–8.

22. Minamoto T, Mai M, Ronai Z. K-ras mutation: early detection in molecular diagnosis and risk assessment of colorectal, pancreas, and lung cancers—a review. Cancer Detect Prev. 2000;24(1):1–12.

23. Telang S, Nelson KK, Siow DL, Yalcin A, Thornburg JM, Imbert-Fernandez Y, et al. Cytochrome c oxidase is activated by the oncoprotein Ras and is required for A549 lung adenocarcinoma growth. Mol Cancer. 2012;11:60.

24. Dejean A, Beuvant B, Bunoust O, Beauvoit B, Guerin B, Rigoulet M. Activation of Ras and the downstream cascades increase the mitochondrial enzyme content of respiratory competent yeast. Biochem Biophys Res Commun. 1999;258(1):87–93.

25. Wang Z, Fan M, Candas D, Zhang TQ, Qin L, Eldridge A, et al. Cyclin B1/Cdk1 coordinates mitochondrial respiration for cell-cycle G2/M progression. Dev Cell. 2014;29(2):217–32.

26. Sequist LV, Heist RS, Shaw AT, Fidias P, Rosovsky R, Temel JS, et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol. 2011;22(12):2616–24.

27. Chen G, Gharib TG, Huang CC, Thomas DG, Shedden KA, Taylor JM, et al. Proteomic analysis of lung adenocarcinoma: identification of a highly expressed set of proteins in tumors. Clin Cancer Res. 2002;8(7):2298–305.

28. Berwick DC, Hsiao HE, Hosseini KM, Klar J, Tavare JM. The identification of ATP-citrate lyase as a protein kinase B (Akt) substrate in primary adipocytes. J Biol Chem. 2002;277(37):33895–900.

29. Berwick DC, Hsiao HE, Hosseini KM, Klar J, Tavare JM. The identification of ATP-citrate lyase as a protein kinase B (Akt) substrate in primary adipocytes. J Biol Chem. 2002;277(37):33895–900.
53. Akgul EO, Kurt B, Kurt YG, Cayci T. MtDNA deletions and deletions may also be important in pathogenesis of lung cancer. Respir Med. 2013;107(11):1814.

54. Mi J, Tian G, Liu S, Li X, Ni T, Zhang L, et al. The relationship between altered mitochondrial DNA copy number and cancer risk: a meta-analysis. Sci Rep. 2015;5:10039.

55. Reznik E, Miller ML, Sibnabaagol Y, Riaz N, Sarungbam J, Tickoo SK, et al. Mitochondrial DNA copy number variation across human cancers. Elife. 2016;5:e10769.

56. Lin CS, Lee HT, Lee MH, Pan SC, Ke CY, Chiu AW, et al. Role of mitochondrial DNA copy number alteration in human renal cell carcinoma. Int J Mol Sci. 2016;17(6):814.

57. LeBluus OS, O’Connell JT, Gonzalez-Herrera KN, Wikman H, Pantel K, Haigis MC, et al. PGC-1alpha mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Nat Cell Biol. 2014;16(10):992–1003, 1–15.

58. Viale A, Corti D, Draetta GF. Tumors and mitochondrial respiration: a neglected connection. Cancer Res. 2015;75(18):3685–6.

59. Kuhn KS, Muscaritoli M, Wischmeyer P, Stehle P. Glutamine as indispensable nutrient in oncology: experimental and clinical evidence. Eur J Nutr. 2010;49(4):197–210.

60. Alam MM, Sohoni S, Kalainayakan SP, Garrossian M, Zhang L. Cyclopa-miner tartrate, an inhibitor of Hedgehog signaling, strongly interferes with mitochondrial function and suppresses aerobic respiration in lung cancer cells. BMC Cancer. 2016;16:150.

61. Ellinghaus P, Heisler I, Unterschemmann K, Haerter M, Beck H, Greschat S, et al. BAY 87-2243, a highly potent and selective inhibitor of hypoxia-inducible factor activation has antitumor activities by inhibition of mitochondrial complex I. Cancer Med. 2013;2(5):611–24.

62. Jara JA, Lopez-Munoz R. Metformin and cancer: between the bioenergetic disturbances and the antifolate activity. Pharmacol Res. 2015;101:102–8.

63. Tomasetti M, Nocchi L, Staffolani S, Manzella N, Amati M, Goodwin J, et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest. 2008;118(12):3930–40.

64. Porporato PE. Understanding cachexia as a cancer metabolism syndrome. Oncogenesis. 2016;5:e200.

65. Narsale AA, Caron JA. Role of interleukin-6 in cachexia: therapeutic implications. Curr Opin Support Palliat Care. 2014;8(4):321–7.

66. Keller U. Pathophysiology of cancer cachexia. Support Care Cancer. 1993;1(6):290–4.

67. Gebhard DJ, St Germain M, Haimana J, van der Ploeg L, van Herpen C, et al. Metformin reduces the risk of cancer in patients with type 2 diabetes: an analysis based on the Korean national diabetes program cohort. Medicine (Baltimore). 2018;97(8):e0036.

68. Andrejewski S, Gravel SP, Pollak M, St-Pierre J. Metformin directly acts on mitochondria to alter cellular bioenergetics. Cancer Metab. 2014;2:12.

69. Janzer A, German NJ, Gonzalez-Herrera KN, Asara JM, Haigis MC, Struhl K. Metformin and phenformin deplete tricarboxylic acid cycle and glycolytic intermediates during cell transformation and NTPs in cancer stem cells. Proc Natl Acad Sci USA. 2014;111(29):10574–9.

70. Liu X, Romero IL, Litchfield LM, Lengyel E, Locasale JW. Metformin targets central carbon metabolism and reveals mitochondrial require-ments in human cancers. Cell Metab. 2016;24(5):728–39.

71. Galluzzi L, Kepp O, Vander Heiden MG, Kroemer G. Metabolic targets for cancer therapy. Nat Rev Drug Discov. 2015;12(11):e236.e7–46.

72. Icard P, Kafarova P, Steyaert J, Schwartz L, Lincert H. The metabolic cooperation between cells in solid cancer tumors. Biochim Biophys Acta. 2014;1846(1):216–25.
98. Zhang G, Frederick DT, Wu L, Wei Z, Krepler C, Srinivasan S, et al. Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors. J Clin Invest. 2016;126(5):1834–56.
99. Yang T, Ng WH, Chen H, Chemchopbun K, Huynh TH, Go ML, et al. Mitochondrial-targeting MET kinase inhibitor kills erlotinib-resistant lung cancer cells. ACS Med Chem Lett. 2016;7(8):807–12.
100. Gao C, Shen Y, Jin F, Mao Y, Qiu X. Cancer stem cells in small cell lung cancer cell line H446: higher dependency on oxidative phosphorylation and mitochondrial substrate-level phosphorylation than non-stem cancer cells. PLoS ONE. 2016;11(5):e0154576.
101. Ozsvári B, Bonuccelli G, Sanchez-Alvarez R, Foster R, Sotgia F, Lisanti MP. Targeting flavin-containing enzymes eliminates cancer stem cells (CSCs), by inhibiting mitochondrial respiration: vitamin B2 (Riboflavin) in cancer therapy. Aging (Albany NY). 2017;9(12):2610–28.
102. Weinberg F, Hamanaka R, Wheaton WW, Weinberg S, Joseph J, Lopez M, et al. Mitochondrial metabolism and ROS generation are essential for Ras-mediated tumorigenicity. Proc Natl Acad Sci USA. 2010;107(19):9788–93.
103. Shanmugasundaram K, Nayak BK, Friedrichs WE, Kaushik D, Rodriguez R, Block K. NOX4 functions as a mitochondrial energetic sensor coupling cancer metabolic reprogramming to drug resistance. Nat Commun. 2017;8(1):997.
104. Farge T, Saland E, de Toni F, Aroua N, Hosseini M, Perry R, et al. Chemotherapy-resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism. Cancer Discov. 2017;7(7):716–35.
105. Zhang C, Skamagki M, Liu Z, Ananthanarayanan A, Zhao R, Li H, et al. Biological significance of the suppression of oxidative phosphorylation in induced pluripotent stem cells. Cell Rep. 2017;21(8):2058–65.
106. Gießel RJ, Feruglio PF, Pathania D, Yang KS, Kilcoyne A, Vrioni C, et al. Computational imaging reveals mitochondrial morphology as a biomarker of cancer phenotype and drug response. Sci Rep. 2016;6:32985.
107. George J, Ahmad N. Mitochondrial sirtuins in cancer: emerging roles and therapeutic potential. Cancer Res. 2016;76(9):2500–6.
108. Kim SW, Lee YK, Lee JY, Hong JH, Kang D. PEglyated anticancer-carbon nanotubes complex targeting mitochondria of lung cancer cells. Nano-technology. 2017;28(46):465102.
109. Dey S, Kumari S, Kalainayakan SP, Campbell J 3rd, Ghosh P, Zhou H, et al. The vascular disrupting agent combretastatin A-4 phosphate causes prolonged elevation of proteins involved in heme flux and function in resistant tumor cells. Oncotarget. 2018;9(3):4000–101.
110. Solaimi G, Baracca A, Lenaz G, Sgarbi G. Hypoxia and mitochondrial oxidative metabolism. Biochim Biophys Acta. 2010;1797(6–7):1171–7.
111. Chandel NS, Budinger GR, Choe SH, Schumacker PT. Cellular respiration during hypoxia: Role of cytochrome oxidase as the oxygen sensor in hepatocytes. J Biol Chem. 1997;272(30):18808–16.
112. Tormos RV, Chandel NS. Inter-connection between mitochondria and HIFs. J Cell Mol Med. 2010;14(4):795–804.
113. Andrew TL, Riley PG, Dailey HA. Regulation of heme biosynthesis in higher animals. In: Dailey HA, editor. Biosynthesis of heme and chlorophylls. New York: Green Pub. Associates and Wiley-Interscience; 1990. p. 183–232.
114. Chance B. Reaction of oxygen with the respiratory chain in cells and tissues. J Gen Physiol. 1965;49(1):163–95.
115. Labbe-Bois R, Labbe P. Tetrapyrrole and heme biosynthesis in the yeast Saccharomyces cerevisiae. In: Dailey HA, editor. Biosynthesis of heme and chlorophylls. New York: Green Pub. Associates and Wiley-Interscience; 1990. p. 235–85.
116. McKeown SP. Defining normoxia, physioxia and hypoxia in tumours-implications for treatment response. Br J Radiol. 2014;87(1035):20130676.